Titleist Asset Management’s Immunovant IMVT Stock Holding History

Titleist Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7,000	Closed	-$269K	–	228
2023 Q3	$269K	Buy	+7,000	New	+$158K	0.06%	181

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Titleist Asset Management's IMVT Position: Q4 2023 in Review

Titleist Asset Management sold out of Immunovant (IMVT) in Q4 2023, closing a stake of 7,000 shares — an estimated $269K sold.

Titleist Asset Management first reported a position in IMVT in Q3 2023 and held it in 1 quarter. The position peaked at $269K in Q3 2023. 228 funds tracked by Wall St. Rank hold IMVT as of Q4 2023.

Titleist Asset Management reported no remaining Immunovant position as of Q4 2023 after selling out during the quarter.
Titleist Asset Management sold 7,000 Immunovant shares in Q4 2023, an estimated $269K.
Titleist Asset Management first reported a position in Immunovant in Q3 2023 and held it in 1 quarter.
Titleist Asset Management's Immunovant position peaked at $269K in Q3 2023.
228 funds tracked by Wall St. Rank held Immunovant as of Q4 2023.

Based on Titleist Asset Management's 13F filing for Q4 2023, filed 15 Feb 2024.